Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
35 Results for "
PD II
" in MedChemExpress (MCE) Product Catalog:
Products (35)
35 Results for "PD II" in MCE Product Catalog:
Cat. No.: HY-156573
CAS No.: 2830643-06-4
DGKα/ζ-IN-1 (Compound II) is a DGK target inhibitor. DGKα/ζ-IN-1 can enhance the function of T cells, and has a synergistic effect with PD-1, which has therapeutic effects IN both immune and tumor .
Cat. No.: HY-120238
CAS No.: 145543-03-9
Target:
Research Areas:
RG 13647 is an AT2-selective ligand. RG 13647 is an analog of PD 123177 (HY-121767). RG 13647 shows weak
activity in competing for [125I]angiotensin II binding with an IC50 value of 100 μM. RG 13647 can be used for research of cardiovascular disease .
Cat. No.: HY-10581B
CAS No.: 316819-28-0
Synonyms: AM-1155 mesylate; BMS-206584 mesylate; PD135432 mesylate
Target:
Research Areas:
Gatifloxacin mesylate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin mesylate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin mesylate can be used to treat bacterial conjunctivitis in vivo.
Cat. No.: HY-10581AS
Synonyms: AM-1155-d3 hydrochloride; BMS-206584-d3 hydrochloride; PD135432-d3 hydrochloride
Cat. No.: HY-10581AR
CAS No.: 121577-32-0
Synonyms: AM-1155 hydrochloride (Standard); BMS-206584 hydrochloride (Standard); PD135432 hydrochloride (Standard)
Research Areas:
Gatifloxacin (hydrochloride) (Standard) is the analytical standard of Gatifloxacin (hydrochloride). This product is intended for research and analytical applications. Gatifloxacin hydrochloride (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin hydrochloride inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml)[1]. Gatifloxacin hydrochloride can be used to treat bacterial conjunctivitis in vivo.
Cat. No.: HY-W700069
CAS No.: 1190043-25-4
Synonyms: AM-1155-d4; BMS-206584-d4; PD135432-d4
Cat. No.: HY-10581CR
CAS No.: 180200-66-2
Synonyms: AM-1155 sesquihydrate (Standard); BMS-206584 sesquihydrate (Standard); PD135432 sesquihydrate (Standard)
Research Areas:
Gatifloxacin (sesquihydrate) (Standard) is the analytical standard of Gatifloxacin (sesquihydrate). This product is intended for research and analytical applications. Gatifloxacin sesquihydrate (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin sesquihydrate inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50 = 0.109 μg/ml) . Gatifloxacin sesquihydrate can be used to treat bacterial conjunctivitis?in vivo.
Cat. No.: HY-10581R
CAS No.: 112811-59-3
Synonyms: AM-1155 (Standard); BMS-206584 (Standard); PD135432 (Standard)
Research Areas:
Gatifloxacin (Standard) is the analytical standard of Gatifloxacin. This product is intended for research and analytical applications. Gatifloxacin (AM-1155; BMS-206584; PD135432) is a potent fluoroquinolone antibiotic with broad-spectrum antibacterial activity. Gatifloxacin inhibits bacterial type II topoisomerases (IC50=13.8 μg/ml for S. aureus topoisomerase IV) and E. coli DNA gyrase (IC50=0.109 μg/ml) . Gatifloxacin can be used to treat bacterial conjunctivitis in vivo.
Cat. No.: HY-102093A
CAS No.: 151801-76-2
ZD 7155 is an AT1R selective antagonist with renal function modulating activity. The effects of ZD 7155 on glomeruli and tubules were measured in 1- (N = 9) and 6-week-old (N = 13) lambs. Pretreatment with ZD 7155 after L-NAME infusion did not alter glomerular function in 1- or 6-week-old lambs. During postnatal development, Ang II modulates the effects of NO on electrolyte handling via AT1R and AT2R. In 6-week-old lambs, selective inhibition of AT1R and AT2R increased the excretion of Na+, K+, and Cl-. In 6-week-old lambs, pretreatment with ZD 7155 and PD 123319 followed by the addition of L-NAME increased urine flow rate by 200%, free water clearance by 50%, and decreased urine osmolality by 40%. The same trends of changes in these variables were also observed when L-NAME was added to ZD 7155 or PD 123319, although to a lesser extent.
Cat. No.: HY-10259AR
CAS No.: 136676-91-0
Research Areas:
PD 123319 ditrifluoroacetate (Standard) is the analytical standard of PD 123319 ditrifluoroacetate (HY-10259A). This product is intended for research and analytical applications. PD 123319 ditrifluoroacetate is a potent, selective AT2 angiotensin II receptor antagonist with IC50 of 34 nM.
Cat. No.: HY-169837
CAS No.: 163239-24-5
Research Areas:
PD-147693 (compound II) is an active metabolite of the presynaptic dopamine autoreceptor agonist CI-1007 and has antipsychotic activity similar to CI-1007 .
Cat. No.: HY-P810477
Synonyms: PAF1 Homolog, Paf1/RNA Polymerase II Complex Component, PD2, F23149_1, RNA Polymerase II-Associated Factor 1 Homolog, Pancreatic Differentiation Protein 2, FLJ11123, Paf1, RNA Polymerase II Associated Factor, Homolog (S. Cerevisiae), Paf1, RNA Polymerase II Associated Factor, Homolog, HPAF1
Cat. No.: HY-181420A
CAS No.: 3029443-36-2
Target:
Research Areas:
BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα inhibitor. BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .
Cat. No.: HY-N20707
CAS No.: 24312-00-3
Category:
Cat. No.: HY-181420
CAS No.: 3029184-80-0
Target:
Research Areas:
(S,R,S)-BBO-11818 is an orally active, highly selective (relative to NRAS and HRAS), non-covalent pan-KRAS inhibitor (IC50=28-120 nM). (S,R,S)-BBO-11818 specifically binds to the Switch-II/Helix 3 pocket, disrupts the KRAS:RAF1 interaction by inducing conformational changes, and blocks the MAPK signaling pathway. (S,R,S)-BBO-11818 exhibits significant anti-tumor activity, which not only inhibits cell proliferation and induces apoptosis, but also drives tumor regression in xenograft models. (S,R,S)-BBO-11818 produces synergistic effects when combined with Cetuximab (HY-P9905), anti-PD-1 antibody or PI3Kα inhibitor. (S,R,S)-BBO-11818 is used in the research of KRAS mutation-related malignancies such as pancreatic cancer, non-small cell lung cancer and colorectal cancer .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
